• CAS
  • |
  • C&EN
  • |
  • Journals
  • |
  • ACS

search site
Advanced Search »
  • Home
  • |
  • About CAS
    • CAS Media Library
    • CAS Quotes
    • Colors of Chemistry
    • 100th Anniversary Celebration
    • Careers at CAS
    • FAQs
    • Directions to CAS
    • Contact Us
  • |
  • Our Expertise
    • CAS Databases
    • Value Added Tools
    • Technical Service and Support
  • |
  • Solutions
    • Researchers
    • IP Professionals
    • Information Professionals
    • Academics
  • |
  • Products & Services
    • SciFinder
    • STN Family of Products
    • Science IP
    • CAS Client Services
    • CAS Document Detective Service
    • CD Products
    • Print Products
  • |
  • Support & Training
    • SciFinder
    • SciFinder Scholar
    • STN
    • STN Express
    • STN AnaVist
    • STN Viewer
    • STN on the Web
    • STN Easy
    • CAS Customer Care
  • |
  • News & Events
    • What's New
    • Press Room
    • News Releases
    • In the News
    • Trade Shows
  • CAS Science Spotlight Home
  • Most Cited Journal Articles 2002-Medical Sciences
  • About
  • What's New
Home   •   Spotlight  •  medsci02  •  Most Cited Journal Articles 2002-Medical Sciences (5)
Most Cited Journal Articles 2002-Medical Sciences
spotlightlogo.gif

Following is a CAS database record representing a highly cited journal article.



CAS subject entries for this document include: Blood vessel, disease; Disease; Neoplasm; and 2 additional concepts.

CAPLUS COPYRIGHT 2003 ACS

TITLE: Angiogenesis in cancer, vascular, rheumatoid and other disease
AUTHOR(S): Folkman, Judah
CORPORATE SOURCE: Children's Hospital and Harvard Medical Sch., Boston, MA, USA
SOURCE: Nature Medicine (New York) (1995), 1(1), 27-31 CODEN: NAMEFI; ISSN: 1078-8956
PUBLISHER: Nature Publishing Co.
LANGUAGE: English
ABSTRACT:
A review with .apprx.72 refs. Recent discoveries of endogenous neg. regulators of angiogenesis, thrombospondin, angiostatin and glioma-derived angiogenesis inhibitory factor, all assocd. with neovascularized tumors, suggest a new paradigm of tumorigenesis. It is now helpful to think of the switch to the angiogenic phenotype as a net balance of pos. and neg. regulators of blood vessel growth. The extent to which the neg. regulators are decreased during this switch may dictate whether a primary tumor grows rapidly or slowly and whether metastases grow at all.

 

Updated 4/26/2007 9:04:43 AM
Home  |  About CAS  |  Our Expertise  |  Solutions  |  Products & Services  |  Support  |  News & Events
Copyright © 2008 American Chemical Society